Abbisko Therapeutics Co., Ltd.

Abbisko Therapeutics Co., Ltd. is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Founded in 2016, the company has established an in-house R&D engine and a pipeline of 10+ small molecule programs focused on oncology, including five programs at the clinical stage. It aims to address unmet medical needs for patients in China and globally.

Abbisko Therapeutics was founded in 2016. Since its inception, the company has established a robust in-house R&D engine underpinned by an outstanding discovery team and a multi-dimensional discovery platform. It has strategically designed and developed a rich pipeline of 10+ small molecule programs focused on oncology, including five programs at the clinical stage.

R&D-driven, clinical-stage biopharmaceutical company focused on small molecule precision oncology and immuno-oncology therapies.

• Pimicotinib (ABSK021)

  CSF-1R inhibitor being developed for TGCT, cGvHD, and solid tumors.

• Irpagratinib (ABSK011)

  FGFR4 inhibitor being developed for FGF19+ HCC.

• Fexagratinib (ABSK091)

  Pan-FGFR inhibitor being developed for FGFR-altered UC.

• ABSK061

  FGFR2/3 inhibitor being developed for solid tumors and ACH.

• ABSK121

  FGFR-resistant mutations inhibitor being developed for solid tumors.

• ABSK112

  EGFR Exon20 inhibitor being developed for NSCLC.

1. 1Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics - 上海和誉生物医药科技有限公司abbisko.com
2. 2Abbisko Therapeutics - 上海和誉生物医药科技有限公司-KNOW MOREabbisko.com